InMed Pharmaceuticals (INM) Operating Expenses (2019 - 2026)

InMed Pharmaceuticals' Operating Expenses history runs 8 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 36.28% year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $10.4 million, a 9.11% increase from a year earlier, with the FY2025 full-year figure at $9.7 million, up 3.83% from the prior year.
• Operating Expenses rose to $2.8 million in Q1 2026 per INM's latest filing, from $2.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $6.8 million in Q2 2022 and bottomed at $2.0 million in Q4 2023.
• The 5-year median for Operating Expenses is $2.3 million (2022), against an average of $2.8 million.
• Across the five-year window, Operating Expenses soared 104.75% in 2022 and sank 69.64% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $2.3 million in 2022, then declined by 16.03% to $2.0 million in 2023, then soared by 37.88% to $2.7 million in 2024, then decreased by 15.77% to $2.3 million in 2025, then advanced by 24.17% to $2.8 million in 2026.
• Per Business Quant, the three latest INM Operating Expenses figures stand at $2.8 million (Q1 2026), $2.3 million (Q4 2025), and $2.2 million (Q3 2025).